EUVIMEDEUVIMED entdecken
Crossref

Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism

Anna Felberg, Michał Bieńkowski, Tomasz Stokowy, Kamil Myszczyński, Zuzanna Polakiewicz, Kamila Kitowska, Rafał Sądej, Frida Mohlin, Alicja Kuźniewska, Daria Kowalska, Grzegorz Stasiłojć, Ilse Jongerius und 6 weitere

Translational Research · 2024

DOI: 10.1016/j.trsl.2024.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2024. Verfasst von Anna Felberg und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1…. Hauptthemen laut MEDLINE: Lung Neoplasms, Complement Factor I. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Science Centre Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While numerous membrane-bound complement inhibitors protect the body's cells from innate immunity's autoaggression, soluble inhibitors like complement factor I (FI) are rarely produced outside the liver. Previously, we reported the expression of FI in non-small cell lung cancer (NSCLC) cell lines. Now, we assessed the content of FI in cancer biopsies from lung cancer patients and associated the results with clinicopathological characteristics and clinical outcomes. Immunohistochemical staining intensity did not correlate with age, smoking status, tumor size, stage, differentiation grade, and T cell infiltrates, but was associated with progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS). Multivariate Cox analysis of low vs. high FI content revealed HR 0.55, 95 % CI 0.32-0.95, p=0.031 for PFS, HR 0.51, 95 % CI 0.25-1.02, p=0.055 for OS, and HR 0.32, 95 % CI 0.12-0.84, p=0.021 for DSS. Unfavorable prognosis might stem from the non-canonical role of FI, as the staining pattern did not correlate with C4d - the product of FI-supported degradation of active complement component C4b. To elucidate that, we engineered three human NSCLC cell lines naturally expressing FI with CRISPR/Cas9 technology, and compared the transcriptome of FI-deficient and FI-sufficient clones in each cell line. RNA sequencing revealed differentially expressed genes engaged in intracellular signaling pathways controlling proliferation, apoptosis, and responsiveness to growth factors. Moreover, in vitro colony-formation assays showed that FI-deficient cells formed smaller foci than FI-sufficient NSCLC cells, but their size increased when purified FI protein was added to the medium. We postulate that a non-canonical activity of FI influences cellular physiology and contributes to the poor prognosis of lung cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsComplement Factor IHumansMaleFemaleMiddle AgedCell Line, TumorCarcinoma, Non-Small-Cell LungAgedPrognosisGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Complement systemImmunohistochemistryInnate immunityLung cancerNSCLC

Substanzen

Complement Factor I

Autor:innen und Institutionen

  • Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1 street, 80-211 Gdańsk, Poland.
  • Department of Pathomorphology, Medical University of Gdańsk, Poland.
  • Scientific Computing Group, IT Division, University of Bergen, Norway.
  • Centre of Biostatistics and Bioinformatics Analysis, Medical University of Gdańsk, Poland.
  • Department of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Poland.
  • Department of Translational Medicine, Lund University, Sweden.

Förderung

  • National Science Centre Poland

Zitieren

APA

Felberg, A., Bieńkowski, M., Stokowy, T., Myszczyński, K., Polakiewicz, Z., Kitowska, K., Sądej, R., Mohlin, F., Kuźniewska, A., Kowalska, D., Stasiłojć, G., Jongerius, I., Spaapen, R., Mesa-Guzman, M., Montuenga, L. M., Blom, A. M., Pio, R., & Okrój, M. (2024). Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism. Translational Research. https://doi.org/10.1016/j.trsl.2024.02.003

Vancouver

Felberg A, Bieńkowski M, Stokowy T, Myszczyński K, Polakiewicz Z, Kitowska K, et al. Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism. Translational Research. 2024. doi:10.1016/j.trsl.2024.02.003

BibTeX
@article{Felberg2024,
  author = {Felberg, Anna and Bieńkowski, Michał and Stokowy, Tomasz and Myszczyński, Kamil and Polakiewicz, Zuzanna and Kitowska, Kamila and Sądej, Rafał and Mohlin, Frida and Kuźniewska, Alicja and Kowalska, Daria and Stasiłojć, Grzegorz and Jongerius, Ilse and Spaapen, Robbert and Mesa-Guzman, Miguel and Montuenga, Luis M and Blom, Anna M and Pio, Ruben and Okrój, Marcin},
  title = {Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism},
  journal = {Translational Research},
  year = {2024},
  doi = {10.1016/j.trsl.2024.02.003}
}
Kostenlos starten →